Back
  1. Home
  2. Profile of Leslie Correia Da Cruz (ULiège)
Profil

Correia Da Cruz Leslie

GIGA Immunobiology - Hematology

Département des sciences cliniques > GIGA

Département des sciences cliniques

See author's contact details
Main Referenced Co-authors
Cerella, Claudia (2)
Diederich, Marc (2)
Lee, Yejin (1)
Paik, Ji Yeon (1)
Park, Jeonghye (1)
Main Referenced Keywords
Acute Meloid Leukemia, Immune Checkpoint, Hematology (1); Adult (1); AML immunoprofiling (1); AML, Hematology, Immunotherapy, Oncology, (1); B7-H1 Antigen (1);
Main Referenced Disciplines
Hematology (4)

Publications (total 4)

The most downloaded
15 downloads
Correia Da Cruz, L., Lee, Y., Paik, J. Y., Park, J., Diederich, M.* , & Cerella, C.*. (August 2025). Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients. Biomedicine and Pharmacotherapy, 189, 118287. doi:10.1016/j.biopha.2025.118287 https://hdl.handle.net/2268/338115

The most cited

1 citations (Scopus®)

Correia Da Cruz, L., Lee, Y., Paik, J. Y., Park, J., Diederich, M.* , & Cerella, C.*. (August 2025). Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients. Biomedicine and Pharmacotherapy, 189, 118287. doi:10.1016/j.biopha.2025.118287 https://hdl.handle.net/2268/338115

Correia Da Cruz, L. (September 2025). Exploring Innovative Methods to Uncover Immune Checkpoint Targets in AML [Poster presentation]. GIGA DAY, Liège, Belgium.

Correia Da Cruz, L., Lee, Y., Paik, J. Y., Park, J., Diederich, M.* , & Cerella, C.*. (August 2025). Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients. Biomedicine and Pharmacotherapy, 189, 118287. doi:10.1016/j.biopha.2025.118287
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Correia Da Cruz, L., Diederich, M., & Cerella, C. (03 July 2024). Immunophenotype profiling classifies AML patient susceptibility to immunotherapies [Poster presentation]. ISCaM, International Society of Cancer Metabolism, Bruxelles, Belgium.

Correia Da Cruz, L. (06 February 2024). Immunophenotype profiling classifies AML patient susceptibility to immunotherapies [Poster presentation]. Televie Seminar, Bruxelles, Belgium.

Contact ORBi